Exelixis, Inc.

How big is Exelixis, Inc.?

As of Jun 18, Exelixis, Inc. has a market capitalization of $11.28 billion, with net sales of $2.30 billion and net profit of $643.57 million over the latest four quarters.

As of Jun 18, Exelixis, Inc. has a market capitalization of 11,277.85 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2,298.92 million, while the sum of Net Profit for the same period is 643.57 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 2,244.20 million and Total Assets at 2,986.98 million.

What does Exelixis, Inc. do?

Exelixis, Inc. is a mid-cap biopharmaceutical company focused on developing and commercializing cancer treatments. As of March 2025, it reported net sales of $555 million and a net profit of $160 million.

Overview: <BR>Exelixis, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of new medicines to manage care and outcomes for people with cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 555 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 160 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 11,277.85 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.48 <BR>Return on Equity: 32.08% <BR>Price to Book: 5.29<BR><BR>Contact Details: <BR>Address: 1851 Harbor Bay Pkwy, ALAMEDA CA: 94502-3016 <BR>Tel: 1 650 8377000 <BR>Website: http://www.exelixis.com

Should I buy, sell or hold Exelixis, Inc.?

Who are in the management team of Exelixis, Inc.?

As of March 2022, the management team of Exelixis, Inc. includes Dr. Stelios Papadopoulos (Independent Chairman), Dr. Michael Morrissey (President and CEO), and several Independent Directors: Dr. Charles Cohen, Mr. Carl Feldbaum, Dr. Maria Freire, Dr. Alan Garber, and Dr. Vincent Marchesi. This team is responsible for the company's strategic direction and management.

As of March 2022, the management team of Exelixis, Inc. includes the following individuals:<BR><BR>- Dr. Stelios Papadopoulos, who serves as the Independent Chairman of the Board and is a Co-Founder of the company.<BR>- Dr. Michael Morrissey, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Charles Cohen, who is an Independent Director.<BR>- Mr. Carl Feldbaum, who is also an Independent Director.<BR>- Dr. Maria Freire, serving as an Independent Director.<BR>- Dr. Alan Garber, who is an Independent Director.<BR>- Dr. Vincent Marchesi, who is another Independent Director.<BR><BR>This team plays a crucial role in guiding the strategic direction and management of Exelixis, Inc.

Is Exelixis, Inc. overvalued or undervalued?

As of July 28, 2025, Exelixis, Inc. is considered attractively valued with a P/E ratio of 17, an EV to EBITDA of 12.68, a PEG ratio of 0.08, strong returns on capital and equity, and a 1-year return of 50.82%, outperforming the S&P 500's 17.14%.

As of 28 July 2025, Exelixis, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 17, an EV to EBITDA of 12.68, and a PEG ratio of 0.08, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Exelixis has a lower P/E ratio than Neurocrine Biosciences, Inc. at 37.08 and a more favorable EV to EBITDA ratio than Viatris, Inc. at 44.86. The company's strong return on capital employed (ROCE) of 74.07% and return on equity (ROE) of 32.08% further support its valuation. Notably, Exelixis has outperformed the S&P 500 across multiple periods, with a 1-year return of 50.82% compared to the S&P 500's 17.14%, reinforcing the attractiveness of its current valuation.

Is Exelixis, Inc. technically bullish or bearish?

As of October 24, 2025, Exelixis, Inc. is in a mildly bearish trend, with mixed technical indicators, having outperformed the S&P 500 year-to-date and over the past year, but underperformed in the short term.

As of 24 October 2025, the technical trend for Exelixis, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and moving averages both indicating a bearish outlook. The KST is bearish on the weekly and bullish on the monthly, while the RSI shows a bullish signal on the weekly but no signal on the monthly. Additionally, the Bollinger Bands present a bearish signal on the weekly and a mildly bullish signal on the monthly. <BR><BR>In terms of performance, Exelixis has outperformed the S&P 500 on a year-to-date basis with a return of 16.28% compared to the S&P 500's 15.47%, and it has significantly outperformed over the past year with a return of 37.74% versus 16.90% for the benchmark. However, it has underperformed in the short term, with a 1-week return of -1.35% compared to the S&P 500's 1.92%.